Scope of the Study
An auto-injector is a medical device intended to deliver a dose of a particular drug. Most auto-injectors are spring-loaded syringes. By design, auto-injectors are easy to use and are intended for self-administration by patients, or administration by untrained personnel. Based on the type, the market is segmented into fillable and prefilled auto-injectors. By technology, the market is classified into automated and manual auto-injector. The rising prevalence of chronic diseases among the globe is one of the key factors contributing to the growth of the market.
The market study is being classified by Type (Fillable Auto-injectors and Prefilled Auto-injectors), by Application (Rheumatoid Arthritis, Anaphylaxis, Multiple Sclerosis and Others) and major geographies with country level break-up. According to AMA, the Global Auto-Injectors market is expected to see growth rate of 15.02%
Antares Pharma, Inc. (United States), Biogen Idec, Inc. (United States), Becton, Dickinson and Company (United States), Mylan, Inc. (United States), Pfizer, Inc. (United States), Novartis International AG (Switzerland), Unilife Corporation (United States), Ypsomed Holdings AG (Switzerland), Scandinavian Health Limited (SHL) Group (Taiwan) and Sanofi S. A. (France) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Amedra Pharmaceuticals Llc (United States), Bespak Europe Ltd (United Kingdom), Changzhou Delfu Technology (China), Dali Medical Devices (Israel), Oval Medical Technologies (United Kingdom) and Owen Mumford (United Kingdom).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Auto-Injectors market throughout the predicted period.
Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Auto-Injectors market by Type, Application and Region.
On the basis of geography, the market of Auto-Injectors has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Design, the sub-segment i.e. Standardized Auto-injectors will boost the Auto-Injectors market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Users, the sub-segment i.e. Homecare will boost the Auto-Injectors market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Automated Auto-injectors will boost the Auto-Injectors market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Usability, the sub-segment i.e. Disposable Auto-injectors will boost the Auto-Injectors market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- Increasing Prevalence of Chronic Diseases
- Rising Demand for Medical Drug Injection Devices
- Increasing Incidences of Anaphylaxis and Food Allergies
- Enhanced Drug Delivery System & New Formulations
- Growing Need for Targeted and Sustained Drug Delivery
- Rising Need for Cost-Efficient Delivery of Expensive Medications
- Rising Concerns for the Hazards Related With Needle Stick Injuries
- Increasing Geriatric Population Worldwide
- Increasing Healthcare Expenditure among the Developed Countries
Market Trend
- A General Trend towards Disposable Devices
Restraints
- High Price of the Auto-Injectors
Opportunities
- Technological Advancements in the Product
- Increasing Demand from Developing Economies
- Insurance Reimbursement by the Government
Market Leaders and their expansionary development strategies
Recently, Pfizer has coordinated with the FDA to extend the expiration dates of specific lots of EpiPen 0.3 mg Auto-Injectors and its authorized generic version after review of stability data. Patients should have confidence in using the products from these particular lots as Pfizer works to stabilize supply.
On 14 Feb 2018, AMAG Pharma. Announced U.S. FDA approval for their supplemental New Drug Application for Makena subcutaneous auto-injector drug-device combination product, which was designed as a ready-to-administer treatment to reduce the risk of preterm birth in women who are pregnant with one baby and who unexpectedly delivered one preterm baby in the past.
Key Target Audience
Auto-Injectors Manufacturers, Auto-Injectors Raw Material Suppliers, Auto-Injectors Traders/Distributors, Auto-Injectors Importer/Exporter, Regulatory Bodies & Government Bodies and Downstream Vendors
Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase